Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-Week outcomes from GRACE

Journal of the National Medical Association

Volumn 104, Issue 7-8, 2012, Pages 366-376

  Smith, Kimberly Y ^a   Garcia, Fernando ^b,h   Kumar, Princy ^c   Currier, Judith S ^d   Ryan, Robert ^e   Falcon, Ron ^f   Mrus, Joseph ⁱ   Squires, Kathleen ^g  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Valley AIDS Council   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Tibotec Inc   (United States)

^f Clinical Affairs   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h Garcia Family Health Group   (United States)

ⁱ NONE

Author keywords

HIV AIDS; Race ethnicity

Indexed keywords

DARUNAVIR; RITONAVIR; VIRUS RNA;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GENDER; HEADACHE; HISPANIC; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; POPULATION RESEARCH; POST HOC ANALYSIS; PRIORITY JOURNAL; RACE; RASH; SEX; SEX DIFFERENCE; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN;

EID: 84866880878     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)30179-6     Document Type: Article

References (31)

1. Centers for Disease Control and Prevention. HIV/AIDS surveillance report. Cases of HIV infection and AIDS in the United States and Dependent Areas. Vol 19. Centers for Disease Control and Prevention; 2007. www.cdc.gov/hiv/topics/ surveillance/resources/reports/2007report/pdf/2007SurveillanceReport.pdf. Accessed May 5, 2009.
2. Centers for Disease Control and Prevention. HIV/AIDS among women. August 2008. http://img.thebody.com/cdc/pdfs/women-hiv.pdf. Accessed August 18, 2011.
3. Cargill VA, Stone VE. HIV/AIDS: a minority health issue. Med Clin North Am. 2005;89:895-912. (Pubitemid 40755549)
4. Janssen Therapeutics. PREZISTA (darunavir) tablets. Full product information. www.prezista.com/patients/full-product-information. Accessed April 6, 2009.
5. Currier J, Averitt Bridge D, Hagins D, et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010;153:349-357.
6. Wright D, Hagins D, Averitt-Bridge D, et al. Real-world representation of women and people of color in clinical trials: Learnings from the GRACE (Gender, Race And Clinical Experience) study and ideas for the future. Poster presented at: 13th Annual US Conference on AIDS; October 29-31, 2009; San Francisco, CA.
7. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Antiretroviral drugs using plasma HIV RNA measurements-clinical considerations for accelerated and traditional approval. www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070968.pdf. Accessed October 2002.
8. Hamilton JD, Hartigan PM, Simberkoff MS, et al. Early versus later zidovudine treatment of symptomatic HIV infection. Clin Res. 1991;39:216A. Abstract.
9. Easterbrook PJ, Keruly JC, Creagh-Kirk T, et al. Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease. Zidovudine Epidemiology Study Group. JAMA. 1991;266:2713-2718.
10. Lagakos S, Fischl MA, Stein DS, et al. Effects of zidovudine therapy in minority and other subpopulations with early HIV infection. JAMA. 1991;266:2709-2712.
11. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169-1178. (Pubitemid 46541620)
12. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429-1441.
13. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39-48. (Pubitemid 47017467)
14. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:29-38. (Pubitemid 47017466)
15. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339-354.
16. Smith KY, Kumar PN, Patel P, et al. Differences in virologic response among African-Americans and females regardless of therapy in the HEAT study. Poster presented at: Fifth International AIDS Society conference on HIV pathogenesis, treatment and prevention; July 19-22, 2009; Cape Town, South Africa. Poster MOPEB033.
17. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA. 2006;296:769-781. (Pubitemid 44223101)
18. Riddler S, Haubrich R, DiRienzo G, et al. Effect of baseline characteristics on treatment outcomes in ACTG 5142: a prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection. Poster presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 776.
19. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-2400. (Pubitemid 40065906)
20. Anastos K, Schneider MF, Gange SJ, et al. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr. 2005;39:537-544. (Pubitemid 41098467)
21. Barron Y, Cole SR, Greenblatt RM, et al. Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy. AIDS. 2004;18:1579-1584. (Pubitemid 39037482)
22. Weintrob AC, Grandits GA, Agan BK, et al. Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr. 2009;52:574-580.
23. Turner BJ, Cunningham WE, Duan N, et al. Delayed medical care after diagnosis in a US national probability sample of persons infected with human immunodeficiency virus. Arch Intern Med. 2000;160:2614-2622.
24. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21:395-402.
25. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370:49-58. (Pubitemid 47023100)
26. Gwadz MV, Leonard NR, Nakagawa A, et al. Gender differences in attitudes toward AIDS clinical trials among urban HIV-infected individuals from racial and ethnic minority backgrounds. AIDS Care. 2006;18:786-794. (Pubitemid 44395525)
27. Smith KY. Paying the price for late starts and early stops: racial and sex disparities in HIV-related mortality. Clin Infect Dis. 2009;49:1579-1581.
28. Cunningham WE, Andersen RM, Katz MH, et al. The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the United States. Med Care. 1999;37:1270-1281.
29. Losina E, Schackman BR, Sadownik SN, et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis. 2009;49:1570-1578.
30. Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr. 2005;38:96-103. (Pubitemid 40094126)
31. Nelson A. Unequal treatment: confronting racial and ethnic disparities in health care. J Natl Med Assoc. 2002;94:666-668.